- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Protections for Pre-existing Conditions; Shareholders Approve Cigna–Express Scripts Deal; Aspirin and CV Risk
GOP senators have introduced legislation they say would protect provisions for preexisting conditions under the Affordable Care Act; Cigna shareholders have voted in favor of the acquisition of pharmacy benefit manager Express Scripts; and study results show that aspirin does not lower cardiovascular (CV) risk in the long-term.
GOP Senators Introduce Bill to Protect Preexisting Conditions
GOP senators have introduced legislation that they say would preserve provisions for people with preexisting conditions under the Affordable Care Act, reported The Hill. The senators said their bill would amend federal law to guarantee access to health insurance for all Americans, including those with preexisting conditions. The legislation would also prevent insurers from increasing premiums for individuals with preexisting conditions. However, critics say the bill would allow insurers to exclude coverage of preexisting conditions.
Shareholders Approve Cigna—Express Scripts Deal
Cigna shareholders have approved the proposed $52 billion acquisition of pharmacy benefit manager Express Scripts. According to Reuters, 90% of shareholders voted in favor of the merger, which is expected to close by the end of 2018. The approval follows Carl Icahn’s attempt to sway shareholders against the deal.
Aspirin Does Not Lower CV Risk in Long-Term
According to study results coming out of the Aspirin to Reduce Risk of Initial Vascular Events trial, a daily dose of 100 mg of aspirin was not associated with a reduction in long-term risk for cardiovascular (CV) or cerebrovascular events. The trial randomly assigned over 12,000 nondiabetic adults with multiple CV risk factors but no history of CV events, reported Medscape.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
